SCHEMBL20628948

SCHEMBL20628948

CCCCOC(=O)c1ccc(Cn2c3c(c4ccccc42)C2C(=O)N(C)CC(=O)N2CC3)cc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 15/20 0.55
▸ HDAC2 Q92769 8/20 0.55
▸ HDAC8 Q9BY41 8/20 0.55
▸ HDAC1 Q13547 4/20 0.43
▸ HDAC4 P56524 3/20 0.43
▸ HDAC10 Q969S8 3/20 0.43
▸ HDAC3 O15379 2/20 0.43
▸ HDAC7 Q8WUI4 2/20 0.43
▸ HDAC11 Q96DB2 2/20 0.43
▸ HDAC5 Q9UQL6 2/20 0.43
▸ NCOR2 Q9Y618 2/20 0.43
▸ HDAC9 Q9UKV0 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20635514 0.89 HDAC6 (0.70) HDAC6HDAC2HDAC8HDAC1HDAC4
SCHEMBL20629250 0.86 HDAC6 (0.57) HDAC6HDAC2HDAC8HDAC1HDAC4
SCHEMBL20605315 0.85 HDAC6 (0.62) HDAC6HDAC2HDAC8HDAC1HDAC4
SCHEMBL22487712 0.85 HDAC2 (0.55) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL20605285 0.83 HDAC6 (0.77) HDAC6HDAC2HDAC8HDAC1HDAC4
SCHEMBL20629340 0.83 HDAC6 (0.48) HDAC6HDAC2HDAC8HDAC1HDAC10
SCHEMBL20629554 0.79 HDAC6 (0.54) HDAC6HDAC2HDAC8HDAC1HDAC4
SCHEMBL17520445 0.77 HDAC6 (0.70) HDAC6HDAC2HDAC8HDAC1HDAC4
SCHEMBL20605229 0.76 HDAC6 (0.56) HDAC6HDAC2HDAC8HDAC1HDAC4
SCHEMBL20628946 0.74 HDAC6 (0.41) HDAC6HDAC2HDAC8HDAC1HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11198694-B2 HDAC6 inhibitors, with improved solubility and their uses UNIVERSITÄT REGENSBURG (DE) 2021-12-14 — — US disclosed
US-20200308174-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2020-10-01 — — US disclosed
WO-2019007836-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES UNIVERSITÄT REGENSBURG (DE) 2019-01-10 — — WO disclosed
EP-3424925-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES Universität Regensburg (DE) 2019-01-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11198694-B2 HDAC6 inhibitors, with improved solubility and their uses HDAC6, HDAC1, HDAC5 HDAC6 1/4885HDAC2 4/4885HDAC8 6/4885
US-20200308174-A1 NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES HDAC6, HDAC1, HDAC2 HDAC6 1/4885HDAC2 3/4885HDAC8 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback